By signing a Memorandum of Understanding with leading Russian pharmaceutical holding companies National Immunobiological Company (Nacimbio) and Pharmstandard, Kedrion Biopharma further strengthens its presence in Russia.
Kedrion Biopharma and Nacimbio, part of the State-owned Rostec group, whose mission is to reduce Russian dependence from the importation of life-saving human plasma derived therapies, are joined by new partner Pharmastandard, a leading Russian company specializing in the development and manufacturing of pharmaceutical products.
This Italian-Russian partnership aims to implement a joint program that will lead to manufacturing plasma-derived products in the Russian Federation; specifically, it aims to finalize the construction of production plant in Kirov, Russia.
The parties are committed to establishing – by January 2017 – a joint venture, shares in which will be owned by Nacimbio (37.5%), Pharmastandard (37.5%) and Kedrion (25%). The joint venture will determine the industrial plan for, and complete the construction of, the Kirov-based plant. In the new organization, Kedrion will uphold its role as principal technological partner, whereas Pharmastandard steps in to provide financial backing.
“The Memorandum signed today is the basis for the successful implementation of a project that is a key priority for Russian healthcare” – commented Sergey Chemezov, CEO of the State Corporation Rostec, at the signing of the document.
“Nacimbio was created for implementing multilevel projects such as this – stated Mariam Khubieva, CEO of Nacimbio; we will make every effort, and engage the country’s best resources, to ensure the production facility begins its operations within the set deadline”.
Paolo Marcucci, CEO of Kedrion Biopharma, stressed the importance of the Memorandum for the company: “We strongly believe in this joint venture with Nacimbio and Pharmstandard, two leading Russian pharmaceutical players. The entire project, and the completion of the production facility in Russia, represent a further milestone in the long-term international growth strategy pursued by our company”.
“For Pharmstandard, entering this joint venture means supporting the common effort towards making Russia independent of plasma product imports”, stated the Operations Director of Pharmstandard, Vladimir Chupikov.
